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Background: Although it is well known that drug pressure selects for drug-resistant parasites, the role of
transmission reduction by insecticide-treated bed nets (ITNs) on drug resistance remains unclear. In this study,
the drug resistance profile of current and previous first-line anti-malarials in Kenya was assessed within the context
of drug policy change and scale-up of ITNs. National first-line treatment changed from chloroquine (CQ) to
sulphadoxine-pyrimethamine (SP) in 1998 and to artemether-lumefantrine (AL) in 2004. ITN use was scaled-up in
the Asembo, Gem and Karemo areas of western Kenya in 1997, 1999 and 2006, respectively.
Methods: Smear-positive samples (N = 253) collected from a 2007 cross-sectional survey among children in
Asembo, Gem and Karemo were genotyped for mutations in pfcrt and pfmdr1 (CQ), dhfr and dhps (SP), and at
pfmdr-N86 and the gene copy number in pfmdr1 (lumefantrine). Results were compared among the three
geographic areas in 2007 and to retrospective molecular data from children in Asembo in 2001.
Results: In 2007, 69 and 85% of samples harboured the pfmdr1-86Y mutation and dhfr/dhps quintuple mutant,
respectively, with no significant differences by study area. However, the prevalence of the pfcrt-76T mutation
differed significantly among areas (p <0.02), between 76 and 94%, with the highest prevalence in Asembo. Several
2007 samples carried mutations at dhfr-164L, dhps-436A, or dhps-613T. From 2001 to 2007, there were significant
increases in the pfcrt-76T mutation from 82 to 94% (p <0.03), dhfr/dhps quintuple mutant from 62 to 82% (p <0.03),
and an increase in the septuple CQ and SP combined mutant haplotype, K76Y86I51R59N108G437E540, from 28 to 39%.
The prevalence of the pfmdr1-86Y mutation remained unchanged. All samples were single copy for pfmdr1.
Conclusions: Molecular markers associated with lumefantrine resistance were not detected in 2007. More recent
samples will be needed to detect any selective effects by AL. The prevalence of CQ and SP resistance markers
increased from 2001 to 2007 in the absence of changes in transmission intensity. In 2007, only the prevalence of
pfcrt-76T mutation differed among study areas of varying transmission intensity. Resistant parasites were most likely
selected by sustained drug pressure from the continued use of CQ, SP, and mechanistically similar drugs, such as
amodiaquine and cotrimoxazole. There was no clear evidence that differences in transmission intensity, as a result
of ITN scale-up, influenced the prevalence of drug resistance molecular markers.
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Case management of malaria currently relies heavily on
the use of a limited set of effective anti-malarial drugs
which may become compromised by the development
and spread of drug resistance [1]. Parasite resistance to
anti-malarial drugs is driven mainly by drug pressure
but it has been hypothesized that changes in malaria
transmission intensity due to the scale up of vector
control interventions, such as insecticide-treated bed
nets (ITNs), could also affect anti-malarial drug resist-
ance [2]. In areas where drug policy has changed and
transmission-reducing malaria control interventions
have achieved high coverage, monitoring the prevalence
of molecular markers for drug resistance to current
treatment drugs and to previously used drugs could pro-
vide a better understanding of how changes in drug
pressure and the intensity of malaria transmission influ-
ence the profile of molecular markers for anti-malarial
drug resistance.
The role of drug pressure on the emergence of
parasite resistance to anti-malarials has been well de-
scribed [3]. Due to widespread parasite resistance to
chloroquine (CQ) and, subsequently, sulphadoxine-
pyrimethamine (SP), all malaria-endemic countries in
sub-Saharan Africa have adopted artemisinin-based
combination therapy (ACT) as the first-line policy for
treatment of uncomplicated Plasmodium falciparum in-
fection [4]. However, the emergence of reduced sensitiv-
ity to artemisinins in focal areas of Southeast Asia has
prompted global concern [5-10]. Although artemisinin
resistance has not yet been documented on the African
continent [11], monitoring parasite resistance to artemi-
sinins or to ACT partner drugs is vital for malaria con-
trol. In addition, long-term monitoring of parasite
sensitivity to previously withdrawn anti-malarial drugs,
such as CQ, can provide useful surveillance information
if these drugs target similar resistance markers to
current or candidate ACT partner drugs [12].
In addition to drug pressure, many other factors can con-
tribute to the development and spread of drug resistance,
notably the pharmacodynamic properties of anti-malarials,
substandard drugs, inadequate dosing, incomplete compli-
ance, as well as human host factors such as age/immunity,
vector and ecological characteristics [3]. Among these fac-
tors, the relationship between reductions in malaria trans-
mission intensity by vector control tools and drug resistance
is complex and remains unclear due to the limited empirical
evidence available from field studies [13]. In Tanzania, the
short-term use of ITNs was linked to decreased prevalence
of a molecular marker associated with resistance to SP [14]
and, in Zimbabwe, the implementation of indoor residual
spraying (IRS) was associated with a lower risk of CQ
treatment failure and reduced prevalence of CQ-resistant
parasites [15]. However, evaluations of insecticide-treatedcurtains in Burkina Faso [16] and ITNs in western Kenya
five years after their introduction indicated no clear effect
of transmission reduction on the prevalence of resistance
markers for SP and CQ [17]. Despite these conflicting
findings, these studies suggest that changes in malaria
transmission by vector control interventions, which are
key elements of malaria control, might influence anti-
malarial drug resistance.
Molecular markers are useful for monitoring parasite
resistance to anti-malarial drugs. The combination of
the dihydrofolate reductase (dhfr) triple mutant (S108T/
N51I/C59R) with the dihydropteroate synthase (dhps)
double mutant (A437G/K540E) has been associated
with in vivo SP treatment failure [18]. Several single nu-
cleotide polymorphisms (SNPs) in P. falciparum CQ
transporter (pfcrt) gene (C72S, M74I, N75E, N75K and
K76T) and P. falciparum multidrug-resistance 1
(pfmdr1) gene (N86Y, S1034C, N1042D, and D1246Y)
have been linked to CQ resistance [19]. Among these
SNPs, K76T and N86Y remain the most important
[19,20]. Pfcrt-76T has also been associated with in vivo
resistance to amodiaquine (AQ), a 4-aminoquinolone
anti-malarial drug that is both structurally related to
and shares a similar mechanism of action to CQ
[21-23]. In addition, increases in the pfmdr1 copy num-
ber have been associated with in vivo and/or in vitro de-
creased sensitivity to mefloquine and lumefantrine, the
ACT partner drug in artesunate-mefloquine (AM) and
the artemether-lumefantrine (AL), respectively [24-26].
Several in vitro and in vivo studies, conducted mainly in
Africa, have shown that the selection of pfmdr1-N86,
N1042, D1246 and pfcrt-K76 susceptible alleles and
mutant type of pfmdr1-184F was associated with the
development of parasite resistance to lumefantrine
[27-32]. Collectively, these findings suggest that the de-
tection of pfmdr1 copy number and/or pfmdr1 SNPs
and pfcrt-K76 wild type could be useful molecular
markers to monitor resistance to mefloquine and
lumefantrine.
As part of a 2007 annual malaria survey conducted in
three areas of western Kenya, this study assessed the
prevalence of resistance markers to currently and previ-
ously used first-line anti-malarials within the context of
drug policy change and scale-up of ITNs. The specific
objectives were to: 1) determine the prevalence of drug-
resistant molecular markers for CQ, SP and lumefan-
trine after the introduction of AL; 2) assess the relation-
ship between the observed prevalence of drug resistance
markers and differences in transmission intensity, as a
result of ITN scale-up, among three geographically con-
tiguous study areas in 2007; and, 3) compare the preva-
lence of the molecular markers from a subset of 2007
samples with molecular data from a 2001 survey from
the same study area [17].
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Study sites, population and design
This study was integrated into a 2007 annual malaria para-
sitaemia and anaemia cross-sectional survey conducted by
the Kenya Medical Research Institute (KEMRI) and the US
Centers for Disease Control and Prevention (CDC) in three
contiguous areas in western Kenya: the Asembo area
(formerly Rarieda Division, Bondo District), Gem (formerly
Yala and Wagai Divisions, Siaya District) and Karemo
(formerly Karemo Division, Siaya District) [33]. One of the
primary aims of the survey was to evaluate the effect of
malaria control interventions on the community-level
prevalence of malaria parasitaemia and anaemia among
children. History of anti-malarial drugs and bed net use
and dried blood spots (DBS) were obtained from 1,271
(Asembo N= 327, Gem N= 451, Karemo N= 492) partici-
pants during the survey. For the study described here, 253
P. falciparum smear-positive samples, 61 in Asembo, 97 in
Gem and 95 in Karemo, collected from participants
<15 years old were available for genotyping of anti-malarial
drug resistance molecular markers. In order to provide a
temporal description in drug resistance markers, the data
from the 2007 survey in Asembo were compared with mo-
lecular data collected from samples obtained in a 2001
community cross-sectional survey conducted in Asembo
area in children < five years old as part of a randomized
controlled trial of ITNs between 1996 and 2001 [17,34,35].
ITN use has been high in the Asembo and Gem areas
since 1997 and 1999, respectively, when nets were first
distributed to every household as part of an ITN efficacy
trial. ITNs were introduced in Karemo in 2004 and
scaled up in 2006 as part of a mass campaign to distrib-
ute free bed nets to children under the age of five. At
the time of the 2007 survey, the parasitaemia prevalence
in participants <15 years old was different among the
three study areas: 35.8% (95% confidence interval (CI)
29.0-43.0%) in Asembo, 45.4% (95% CI 39.3-51.6%) in
Gem and 50.3% (95% CI 43.3-57.2%) in Karemo
(KEMRI/CDC, unpublished data). In the 2001 survey,
the prevalence of parasitaemia in children < five years
old was 34% in the Asembo area [34]. The entomologic
inoculation rate (EIR) was estimated at four infective
bites per person per year in Asembo and Gem and 20
infective bites per person per year in Karemo in the
2007 survey (KEMRI/CDC, unpublished data) and at 1.3
infective bites per person per year in Asembo area in
2001 [36].
In 1998, SP replaced CQ as first-line treatment policy for
uncomplicated malaria in Kenya. National policy change
from SP to AL was officially announced in 2004, although
AL was not used in the study areas until mid-2006. AQ,
the second-line drug during 1998–2004, temporarily be-
came the first-line drug policy for treatment of uncompli-
cated malaria prior to the implementation of AL in 2006[37,38]. SP remains the recommended drug for intermittent
preventive treatment for malaria in pregnancy (IPTp) in the
country. In addition, cotrimoxazole (CTX, trimethoprim-
sulphamethoxazole) was commonly used for first line treat-
ment of acute respiratory illnesses and also for prevention
of opportunistic infection as a component of HIV care in
western Kenya. CTX, a common antifolate antimicrobial,
has similar anti-malarial properties to SP, by inhibiting dhps
enzyme in the folic acid biosynthetic pathway.
This study was approved by the Ethical Review Commit-
tee of KEMRI, Nairobi, Kenya, the Institutional Review
Board of Michigan State University, and the Institutional
Review Board of CDC, Atlanta, Georgia. Written informed
consent was obtained from parents or legal guardians of
children and written assent was also obtained from the
participants between 13 and 18 years of age.Laboratory methods
DNA extraction
Genomic DNA was purified from DBS using the commer-
cial DNA purification QIAamp® blood mini-kit (Qiagen Inc,
Valencia, CA, USA).Genotyping of mutations in drug resistance genes
SNPs at dhfr-50, 51, 59, 108, 164, and dhps-436, 437, 540,
581, 613 were detected using published pyrosequencing pro-
cedures [39]. Pfcrt codons 72, 73, 74, 75, 76, pfmdr1 codons
86, 184, 1034, 1042, 1246 and ambiguous results at dhfr and
dhps genes were examined using direct sequencing [40].Pyrosequencing
Primary and secondary (nested) polymerase chain reaction
(PCR) primers and pyrosequencing primers were synthe-
sized at the CDC Biotechnology Core Facility, Atlanta, USA.
Wild type and mutant positive controls and no DNA tem-
plate negative controls were included in all experiments.
Samples were run in pyrosequencing 96-well plates on Pyro-
Mark ID (Biotage AB, Uppsala, Sweden) and SNPs were
called using the PyroMark ID 1.0 SNP software (Biotage AB,
Uppsala, Sweden) [39].Direct sequencing
Nested PCR sequence procedures were used [40] and
product sequences were read using Big Dye Terminator
v3.1 cycle sequencing kit on iCycler thermal cycler (Bio-
Rad, Hercules, CA, USA). Dye terminators were cleaned
by precipitating reactions in 70% ethanol and rehydrat-
ing in 10 μL HiDi formamide. Reactions were sequenced
on the 3130 ABI Genetic Analyzer (ABI Prism, Foster
City, CA, USA). The predominant sequence in each
sample was called based on the highest peak for each
SNP.
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Copy number amplification was performed on the samples
that were single infection as determined by the highly poly-
morphic, neutral microsatellite (MS) marker Poly-α [41].
Amplification of pfmdr1 was detected using real-time PCR
(Stratagene MX3005P; Agilent Technologies, Santa Clara,
CA) using published reaction conditions, primer sequences
and probes labelled with 3′ black hole quencher (BHQ) and
5′6-carboxyfluorescein (FAM), for pfmdr1 or 5′ hexachloro-
fluorescein (HEX), for β-tubulin [25]. Each experiment in-
cluded a standard curve with five-fold serial dilutions of
3D7, 3D7 calibrator (one copy), the positive controls Dd2
(three to four copies) and W2Mef (two copies), no DNA
template control, and field samples run in triplicate. Copy
number was calculated using the comparative ΔΔCt method
and rounded to the nearest integer. Samples were repeated
if the threshold cycle (Ct) value was above 32 or if the two-
tailed 95% CI (determined from the individual replicate
ΔΔCt calculations around the copy number estimation)
exceeded 0.4 [25,42].Genetic definitions
All SNPs genotyped were classified as wild type or mu-
tant and analysed individually first. Genotypes related to
SP resistance markers (dhfr, dhps and combined dhfr/
dhps) were defined based on the criteria outlined by
Kublin and colleagues [18]. The dhfr genotype reflected
mutations in dhfr-51, 59 and 108, classified as wild type,
single, double and triple mutants. The dhps genotype
described mutations in dhps-437 and 540, categorized
as wild type, single and double mutants. The combined
dhfr/dhps genotype (mutations in dhfr-51, 59, 108, and
dhps-437, 540) was classified as wild type, single,
double, triple, quadruple, and quintuple mutants.
Haplotypes were also constructed for dhfr codons 50,
51, 59, 108, and 164 and dhps codons 436, 437, 540, 581,
and 613 in the samples that were single infection based
on the neutral MS marker, poly-α. The dhfr/dhps haplo-
types offer information on mutant variants in parasite
populations that cannot be assessed from the genotypes
described above. Pfcrt haplotypes based on codons 72,
73, 74, 75, and 76 and pfmdr1 haplotypes, including co-
dons 86, 184, 1034, 1042, and 1246, were reported based
on direct sequencing data. In addition, CQ and SP com-
bined haplotypes were assembled based on pfcrt-76,
pfmdr1-86, dhfr-51, 59,108, and dhps-437, 540 [43,44] in
the samples that were single infection by poly-α. The
CQ and SP combined haplotypes provide information
on the genetic linkage of mutations in parasites carrying
drug resistance to multiple drugs and also an insight
into potential synergistic effects by the different drug re-
sistance genes on the recovery of sensitive parasites to
individual drug [44,45].Data and statistical analysis
Differences in participant characteristics among the three
study areas in the 2007 survey were analysed using Chi-
square or Fisher’s exact test (when expected cell counts were
less than five) for categorical variables and analysis of vari-
ance (ANOVA) for continuous, normally distributed vari-
ables. Parasite density was log transformed. Anaemia was
defined as haemoglobin level < 11 g/dL. Statistical compari-
sons in the prevalence of all SNP mutations in dhfr, dhps,
pfcrt and pfmdr1 genes and SP resistance genotypes in sam-
ples among the three areas and between the 2001 and 2007
surveys were made using Chi-square tests. All statistical
tests were considered as independent for each molecular
marker. Statistical significance was defined by a two-sided p-
value <0.05. Data and statistical analyses were performed
using SAS software version 9.2 (SAS Institute Inc., Cary,
NC, USA).Results
Characteristics of smear-positive participants at the 2007
survey by study area
Smear-positive participants included in this study from
Asembo, Gem and Karemo were similar in sex and age
distribution, proportion anaemic, presence of gameto-
cytes, fever within two weeks prior to survey, and anti-
malarial drugs taken for fever. Geometric mean parasite
density was low and also similar among the three areas.
However, bed net and ITN use differed significantly be-
tween the study areas (p <0.0001). Reported bed net
(treated or untreated) use in Karemo, Gem and Asembo,
respectively, was 20, 44 and 51%, while ITN use was 7,
31 and 49% (Table 1). In addition, reported fever in last
24 hours differed significantly among the three areas
(p <0.01), 15% for Asembo, 21% for Gem and 36% for
Karemo (Table 1). Notably, self-reported AL use was low
in all study areas, ranging from 0 to 3% (Table 1).Prevalence of drug resistance molecular markers
At the 2007 survey
Since there were differences in the age distributions between
the 2001 and 2007 surveys, the molecular profiles in chil-
dren < five and participants between five and fifteen years of
age were compared in 2007. No significant differences in
molecular profiles were observed between the different age
groups (Additional file 1) and therefore, subsequent compar-
isons between 2001 and 2007 were not adjusted for age.
CQ resistance mutations were highly prevalent; at least
73% of samples in all study areas harboured mutations at
pfcrt-74I, 75K/E, or 76T, and mutations at pfmdr1-86Y,
184F, and 1246Y were detected at 69, 23 and 40%, overall,
respectively (Figure 1). No samples carried mutations
at pfmdr1-1034C, 1042D or pfcrt-72S. The prevalence
of pfcrt-76T mutation, but not pfmdr1-86Y, differed
Table 1 Characteristics of Plasmodium falciparum smear-positive participants at the 2007 survey in western Kenya, by
study area
Characteristic Asembo (n = 61) Gem (n = 97) Karemo (n = 95) p-valuea
Male sex 32/61 (53) 47/96 (49) 43/91 (46) 0.75
Age, years
≤5 24/61 (39) 40/97 (41) 40/95 (42) 0.94
6-15 37/61 (61) 57/97(59) 55/95 (58)
Anaemic, Hb < 11 g/dL 24 (39) 33 (34) 46 (48) 0.12
Parasite density, geometric mean, per uL (95% CI)b 548 (351–935) 513 (374–750) 704 (488–1,091) 0.54
Gametocytes present 9/61 (15) 19/97 (20) 12/95 (13) 0.40
Fever in last two weeks 31/61 (51) 62/95 (64) 47/95 (50) 0.088
Fever in last 24 hours 9/59 (15) 20/95 (21) 34/95 (36) 0.0083*
Drug taken for feverc
Coartem 1/31 (3) 1/61 (2) 0/47 (0) –
Sulphadoxine-pyrimethamine 4/31 (13) 2/61 (3) 2/47 (4) 0.20
Antifolated 7/31(23) 4/61 (7) 3/47 (6) 0.055
Chloroquine 2/31 (7) 3/61 (5) 0/47 (0) –
Amodiaquine 4/31 (13) 5/61 (8) 2/47 (4) 0.37
Other (non-anti-malarial) 24/31(77) 38/61 (62) 28/47 (60) 0.24
Bed net usage
Anye (treated or untreated) 31/61 (51) 42/95 (44) 19/95 (20) <0.0001*
ITNf 30/61 (49) 29/95 (31) 7/95 (7) <0.0001*
Note. Data are proportion (%) of P. falciparum smear-positive participants with molecular data, unless otherwise indicated.
Hb, haemoglobin; CI, confidence interval; ITN, insecticide-treated bed net.
aDerived from overall Chi-square or Fisher’s exact (where expected cell counts were below 5) test for categorical variables or analysis of variance (ANOVA) for
continuous, normally distributed variables.
bAsexual parasite density and the presence of gametocytes were detected by microscopy. Parasite density was log transformed prior to statistical analysis.
cSelf-reported drug use was asked for participants who reported being febrile in the two weeks prior to the survey; participant may have taken multiple drugs to
treat fever.
dSulphadoxine-pyrimethamine or Septrin (cotrimoxazole). eReported sleeping under a bed net the night prior to survey.
fITN use among participants who reported sleeping under a bed net the night prior to survey.
*P <0.05, statistically significant.
Figure 1 Comparison of prevalence of point mutations among study areas. Point mutations in dhfr-51, 59, 108, dhps-437, 540, pfmdr1-86,
184, 1246 and pfcrt-74, 75, 76 by study area. As few mutations were detected at dhfr-50, 164, dhps-436, 581, 613, pfcrt-72, 73 and pfmdr1-1034,
1042, the data are presented in the Results section, but not shown in this Figure. Statistical analysis performed using Chi-square tests. *p <0.05
difference in prevalence mutations between study areas.
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81% in Gem and 76% in Karemo (Figure 1).
The overall prevalence of key SP resistance mutations
at dhfr-51I, 59R, 108N and dhps-437G, 540E exceeded
85% and there was no significant difference in these five
SNPs by study area (Figure 1). All samples were wild
type at dhfr-C50 and dhps-A581. Several mutations that
are usually uncommon in Africa were observed in two
samples at dhfr-164L (one sample in Gem, one in
Karemo), three at dhps-436A (two samples in Gem, one
in Karemo), and one at dhps-613T (Karemo). Combining
all areas, the prevalence of the dhfr triple mutant (dhfr
51I/59R/108N) was 88%, dhps double mutant (dhps
437G/540E) was 96% and combined dhfr/dhps quintuple
mutant (dhfr 51I/59R/108N + dhps 437G/540E) was
85%. These genotypes did not differ significantly by
study area (Figure 2).
Comparison of 2001 and 2007 Asembo surveys
Molecular marker data collected from a 2001 cross-
sectional survey in Asembo area [17] were compared with
the 2007 molecular data in Asembo only. The prevalence of
mutations at pfmdr1-86Y, dhfr-51I,108N and dhps-437G
did not change between time points. A significant increase
in mutations at pfcrt-76T from 82 to 94% (p <0.03), dhfr-
59R from 82 to 93% (p <0.05), and dhps-540E from 83 to
100% (p <0.002) was observed from 2001 to 2007, respect-
ively (Figure 3). Overall, the dhps and combined dhfr/dhps
genotypes differed significantly between 2001 and 2007
(p <0.03). The dhps double mutant (dhps-437G/540E) in-
creased considerably from 79% (2001) to 94% (2007) and
the combined dhfr/dhps quintuple mutant (dhfr 51I/59R/Figure 2 Comparison of prevalence SP drug resistance genotypes am
study area. Statistical analysis performed using Chi-square tests. *p <0.05 di108N+ dhps 437G/540E) was 20 percentage points higher
in 2007 compared to the 2001 prevalence of 62% (Figure 4).
Pfmdr1 gene copy number was determined in the samples
that were single infection determined by the MS marker
Poly-α at years 2001 and 2007. All samples were single copy
for pfmdr1.
Haplotypes of CQ, SP, and CQ and SP markers combined
Haplotypes of CQ resistance markers in the 2007 survey
The results of pfcrt and pfmdr1 haplotypes are presented
by study area (Tables 2 and 3). For pfcrt, 11 different
haplotypes were observed: eight in Asembo, six in Gem
and seven in Karemo. The majority of samples in all
study areas were triple mutant type for pfcrt-74, 75, and
76, haplotype C72V73I74E75T76 (75% in Asembo, 80% in
Gem, 69% in Karemo). The haplotype harbouring an
alternative mutant codon K at 75, C72V73I74K75T76, was
only detected in one sample from Asembo. Importantly,
in Gem and Karemo, 15 and 21% of samples, respectively,
were wild type for all five pfcrt codons (C72V73M74N75K76)
while substantially fewer samples from Asembo were the
wild type haplotype (4%). The remaining eight haplotype
variants carrying either single mutation or double muta-
tions at different codons were present from 1 to 8% in
three study areas.
A total of eight haplotypes were found for pfmdr1, with
all eight of these haplotypes present in Gem and Karemo
but seven present in Asembo. The wild type haplotype
N86Y184S1034N1042D1246 was detected in 11% of samples
from Asembo and 13% of samples in Gem and Karemo.
The predominant haplotypes in all three areas contained a
single mutation at codon 86, Y86Y184S1034N1042D1246 (34%ong study areas. Dhfr, dhps, and combined dhfr/dhps genotypes by
fference in prevalence mutations between study areas.
Figure 3 Comparison of prevalence of point mutations in Asembo area between 2001 and 2007 surveys. Point mutations in dhfr 51, 59,
108, dhps 437, 540, pfmdr1-86 and pfcrt-76 by study year. Statistical analysis performed using Chi-square tests. *p <0.05 difference in prevalence of
mutations between 2001 and 2007.
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tations at codons 86 and 1246, Y86Y184S1034N1042Y1246
(34% in Asembo, 23% in Gem, and 27% in Karemo). The
triple mutant at pfmdr1-86, 184 and 1246, haplotype
Y86F184S1034N1042Y1246, was found in 7% of samples from
Gem, 4% of samples from Karemo and, of note, no sam-
ples from Asembo. The remaining four haplotype variants
with single mutation (codon 184 or 1246) or doubleFigure 4 Comparison of prevalence SP drug resistance genotypes in
combined dhfr/dhps genotypes by study year. Statistical analysis performed
between 2001 and 2007.mutations (codons 184 and 1246 or 86 and 184) were
present from 1 to 11% in three areas.
Haplotypes of SP resistance markers in the 2007 survey
In total, eight different haplotypes were detected at the
2007 survey across all study areas. Four haplotypes were
observed in Asembo, five in Gem and three in Karemo.
Overall, approximately 72% of isolates in all three studyAsembo area between 2001 and 2007 surveys. Dhfr, dhps and
using Chi-square tests. *p <0.05 difference in prevalence of mutations
Table 2 Pfcrt haplotypes at the 2007 survey in western Kenya, by study area
pfcrt
haplotypea
72 73 74 75 76 No.
mutations
Asembo, N (%) Gem, N (%) Karemo, N (%)
(n = 52) (n = 86) (n = 89)
Wild type C tgt V gta M atg N aat K aaa
Mutant S agt I att E gaa T aca
S tct K aaa
C V M N K 0 2 (4) 13 (15) 19 (21)
C V I N K 1 0 (0) 1 (1) 2 (2)
C V M E K 1 0 (0) 1 (1) 0 (0)
C V M N T 1 3 (6) 1 (1) 1 (1)
C V M K T 2 4 (8) 0 (0) 0 (0)
C V M E T 2 1 (2) 0 (0) 3 (3)
C V I N T 2 1 (2) 0 (0) 2 (2)
C V I K K 2 0 (0) 1 (1) 0 (0)
C V I E K 2 1 (2) 0 (0) 1 (1)
C V I K T 3 1 (2) 0 (0) 0 (0)
C V I E T 3 39 (75) 69 (80) 61 (69)
Note. No. = number. Wild type amino acids are shown in normal font, while mutated amino acids are depicted in bold font. aThe construction of the pfcrt
haplotype included codons 72, 73, 74, 75, and 76. All isolates coded for wild type C72 and V73.
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ing quintuple mutations at the key dhfr and dhps codons.
Another major haplotype observed was the quadruple mu-
tant C50I51C59N108I164S436G437E540A581A613 (19%, over-
all). The remaining quadruple haplotypes with different
combination at five codons (I51R59N108A437E540) were
present in four samples in three areas. In Gem, one sam-
ple contained a mutation at dhps-A436 in quintuple mu-
tant and another sample had the dhfr-L164 mutation in
quadruple haplotype. The presence of the dhfr triple mu-
tant without any additional mutations, C50I51R59N108I164-
S436A437K540A581A613, was only observed in one sample
from Karemo (Table 4).Table 3 Pfmdr1 haplotypes at the 2007 survey in western Ken
pfmdr1
haplotypea
86 184 1034 1042 1246
Wild type N aat Y tat S agt N aat D gat
Mutant Y tat F ttt C tgt D gat Y tat
N Y S N D
N Y S N Y
N F S N D
Y Y S N D
N F S N Y
Y F S N D
Y Y S N Y
Y F S N Y
Note. No. = number. Wild type amino acids are shown in normal font, while mutat
a The construction of the pfmdr1 haplotype included codons 86, 184, 1034, 1042, anComparison of haplotypes of CQ and SP resistance markers
combined between 2001 and 2007
CQ and SP combined haplotypes, based on pfcrt-76,
pfmdr1-86, dhfr-51, 59, 108, and dhps-437, 540, were con-
structed to determine if there is linkage between CQ resist-
ance genes and the accumulation of SP resistance genes.
The combined haplotypes were compared among study
areas in 2007 and between 2001 and 2007. Overall, fewer
haplotypes were observed at 2007 (seven haplotypes) com-
pared to 2001 (23 haplotypes). In the 2007 survey, two novel
haplotypes were observed: T76Y86I51R59N108A437E540 (six
mutations) in Asembo and K76N86I51R59N108G437K540 (four
mutations) in Gem. Most notably, the prevalence of theya, by study area
No.
mutations
Asembo, N (%) Gem, N (%) Karemo, N (%)
(n = 47) (n = 75) (n = 70)
0 5 (11) 10 (13) 9 (13)
1 2 (4) 8 (11) 2 (3)
1 5 (11) 6 (8) 7 (10)
1 16 (34) 20 (27) 22 (31)
2 1 (2) 3 (4) 1 (1)
2 2 (4) 6 (8) 7 (10)
2 16 (34) 17 (23) 19 (27)
3 0 (0) 5 (7) 3 (4)
ed amino acids are depicted in bold font.
d 1246. All isolates coded for wild type S1034 and N1042.
Table 4 Haplotypes for dhfr and dhps resistance markers combined at the 2007 survey in western Kenya, by study area
SP
haplotypea
dhfr
51
dhfr
59
dhfr
108
dhfr
164
dhps
436
dhps
437
dhps
540
No.
mutations
Asembo, N (%)
(n = 17)
Gem, N (%)
(n = 32)
Karemo, N (%)
(n = 25)
Wild type N aat C tgt S agc I ata S tct A gct K aaa
Mutant I att R cgt N aac L tta A gct G ggt E gaa
I R N I S A K 3 0 (0) 0 (0) 1 (4)
N R N I S G E 4 2 (12) 0 (0) 0 (0)
I C N I S G E 4 3 (18) 6 (19) 5 (20)
I R N I S G K 4 0 (0) 1 (3) 0 (0)
I R N I S A E 4 1 (6) 0 (0) 0 (0)
I R N I S G E 5 11 (65) 23 (72) 19 (76)
I C N L S G E 5 0 (0) 1 (3) 0 (0)
I R N I A G E 6 0 (0) 1 (3) 0 (0)
Note. SP = sulphadoxine-pyrimethamine; No. = number. Wild type amino acids are shown in normal font, while mutated amino acids are depicted in bold font.
All samples were single infection for the microsatellite marker poly-α.
aThe construction of the SP haplotype included dhfr-50, 51, 59, 108, 164 and dhps-436, 437, 540, 581, 613. All samples coded for wild type C at dhfr-50, A at
dhps-581, and A at dhps-613.
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creased from 28% in 2001 to 39% in 2007 in the Asembo
area. It was also noted that 48 and 41% of parasite isolates
from Gem and Karemo, respectively, carried the septuple
mutant haplotype in 2007 (Table 5).
Discussion
The objective of this study was to assess the effect of
changes in drug treatment policy and ITN scale-up on re-
sistance markers for CQ, SP and lumefantrine. At the 2007
survey, only the prevalence of pfcrt-76T mutation differed
among study areas. The prevalence of CQ and SP resistance
markers increased from 2001 to 2007 despite drug policy
change. No molecular marker evidence for lumefantrine re-
sistance was detected.
In order to address the study objective, qualitative rank-
ings of transmission intensity were determined based on
the proxy measures of ITN use, EIR, years since ITN
scale-up and malaria prevalence. Collectively, these mea-
sures indicate that in 2007 a higher level of transmission
in Karemo (ITN scale-up in 2006, ITN usage 7%, EIR 20
and parasite prevalence 50%) than in Asembo and Gem
(ITN scale-up in 1997 and 1999, ITN usage 31-49%, EIR 4
and parasite prevalence 36-45%). In Asembo, there was no
significant change in parasite prevalence and EIR between
2001 and 2007, suggesting that the intensity of malaria
transmission was similar between the two time points. In
1998, SP was introduced as first-line treatment for uncom-
plicated malaria, followed by AL in 2006. While these
changes occurred in an uncontrolled manner, it is useful
to describe how these broad programmatically induced
shifts in policies may have affected molecular profiles of
anti-malarial drug resistance in this study.
A previous study conducted in Malawi observed a re-
turn of wild type pfcrt-K76 molecular marker and CQefficacy 12 years after CQ was withdrawn [46]. In Kenya,
CQ was replaced by SP as the national first-line treatment
policy in 1998. A study conducted in coastal Kenya from
1993 to 2006 reported that following the policy change to
SP, the prevalence of wild type pfcrt-K76 also increased, al-
though at a slower rate than in Malawi [47]. However, this
study showed a significant increase in the prevalence of
pfcrt-76T mutation from 76% in 2001 to 94% in 2007.
Data from a study conducted between 1996 and 2001 in
the same area of western Kenya [17] and this study
(Table 1) indicate that CQ was still used in this study area
despite policy change. The continued use of CQ after pol-
icy change, although limited, could account for the ob-
served significant increase in prevalence of pfcrt-76T
mutation. Between 2004 and 2006, AQ was used tempor-
arily as the first-line drug for treatment of uncomplicated
malaria prior to the implementation of AL in 2006 and
self-reported use of AQ was also observed in the current
study (Table 1). Previous reports showed that the pfcrt
haplotype, S72V73M74N75T76, is associated with AQ treat-
ment failure [22,23]. It is possible that the continued in-
crease in the prevalence of pfcrt-76T mutation over time
could be partially driven by the drug pressure derived
from the use of AQ even though all samples were wild
type at pfcrt -C72 (Table 2). In contrast, the prevalence of
pfmdr1-86Y mutation remained unchanged over time.
The significant increase in prevalence of parasites har-
bouring pfcrt-76T mutation but not pfmdr1-86Y mutation
over time further support that CQ and/or AQ use selects
for mutations in pfcrt [19,21,22,48,49].
Similarly, significant increases in the prevalence of the
dhps double mutant and the dhfr/dhps quintuple mutant
genotypes were observed (Figure 4) from 2001 to 2007, as
well as the emergence of mutations at dhfr-164L, dhps-
436A and dhps-613T in several 2007 samples. In the
Table 5 Haplotypes for CQ and SP resistance markers combined at the 2001 (Asembo) and 2007 (Asembo, Gem, and
Karemo) western Kenya surveys
CQ and SP
haplotypea
crt
76
mdr1
86
dhfr
51
dhfr
59
dhfr
108
dhps
437
dhps
540
No.
mutations
Asembo 2001*
N (%) (n = 111)
Asembo 2007,
N (%) (n = 18)
Gem 2007,
N (%) (n = 31)
Karemo 2007,
N (%) (n = 22)
Wild type K aaa N aat N aat C tgt S agc A gct K aaa
Mutant T aca Y tat I att R cgt N aac G ggt E gaa
K N I C N A K 2 1 (1) 0 (0) 0 (0) 0 (0)
T N I C N A K 3 1 (1) 0 (0) 0 (0) 0 (0)
T Y I C N A K 4 3 (3) 0 (0) 0 (0) 0 (0)
T Y N R N A K 4 1 (1) 0 (0) 0 (0) 0 (0)
K Y I R N A K 4 1 (1) 0 (0) 0 (0) 0 (0)
T N I R N A K 4 2 (2) 0 (0) 0 (0) 0 (0)
T N I C N G K 4 1 (1) 0 (0) 0 (0) 0 (0)
T N N R N G K 4 2 (2) 0 (0) 0 (0) 0 (0)
K N I R N G K 4 0 (0) 0 (0) 1 (3) 0 (0)
K N I C N G E 4 1 (1) 1 (6) 1 (3) 0 (0)
T Y I R N G K 5 2 (2) 0 (0) 0 (0) 0 (0)
T Y I C N G K 5 2 (2) 0 (0) 0 (0) 0 (0)
K Y I R N G K 5 1 (1) 0 (0) 0 (0) 0 (0)
T N I R N G K 5 1 (1) 0 (0) 0 (0) 0 (0)
K Y I C N G E 5 3 (3) 0 (0) 2 (7) 1 (5)
T N I C N G E 5 7 (6) 0 (0) 3 (10) 1 (5)
T N N R N G E 5 4 (4) 1 (6) 0 (0) 0 (0)
K N I R N G E 5 3 (3) 0 (0) 0 (0) 1 (5)
T Y I R N G K 6 4 (4) 0 (0) 0 (0) 0 (0)
T Y I R N A E 6 0 (0) 1 (6) 0 (0) 0 (0)
T Y N R N G E 6 5 (5) 1 (6) 0 (0) 0 (0)
T Y I C N G E 6 11 (10) 2 (11) 1 (3) 3 (14)
K Y I R N G E 6 1 (1) 0 (0) 0 (0) 3 (14)
T N I R N G E 6 23 (21) 5 (28) 8 (26) 4 (18)
T Y I R N G E 7 31 (28) 7 (39) 15 (48) 9 (41)
Note. CQ = chloroquine; SP = sulphadoxine-pyrimethamine; No. = number. Wild type amino acids are shown in normal font, while mutated amino acids are
depicted in bold font. All samples were single infection for the microsatellite marker poly-α.
aThe construction of the CQ-SP haplotype included pfcrt-76, pfmdr1 -86, dhfr-51, 59, 108, and dhps-437, 540.
*Data are derived from a previous study [17].
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quintuple mutant haplotype parasites, C50I51R59N108I164S
436G437E540A581A613 (Table 4). The increased selection of SP
drug resistance parasites over time could be attributed to
several factors. First, although at government health facil-
ities, AL replaced SP as the first-line treatment for uncom-
plicated malaria in children in mid-2006, SP was still being
used in the study area through 2007 (Table 1). This may
have resulted in sustained drug pressure on these markers.
Second, as SP remains the recommended drug for IPTp in
the country, it is possible that pregnant women could serve
as infectious reservoir for sustaining and circulating SP re-
sistance parasites [50]. Third, the high use of CTX as an
antibiotic treatment for respiratory infections and for the
prevention of opportunistic infections in HIV-infectedindividuals might have also selected for SP drug resistance
markers. Therefore, it is necessary to monitor SP molecular
markers for an extended period in both the general popula-
tion and pregnant women after a drug policy change leading
to reduced SP drug pressure on the whole population.
The selection of wild type pfmdr1-N86, N1042, D1246,
pfcrt-K76 and mutant type of pfmdr1-184F, and increased
pfmdr1 gene copy number have been associated with de-
creased lumefantrine sensitivity [27-30,32]. From 2001 to
2007, the prevalence of the pfmdr1-N86 wild type remained
statistically unchanged from 26.6 to 29.4% (Table 1), while a
significant increase in the pfcrt-76T mutation was found.
Multiple copies of pfmdr1 were not detected in samples at
either time point. All 2007 samples were wild type pfmdr1-
N1042 while 23.3% carried the mutation pfmdr1-184F and
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genotyped for these three codons. The unchanged wild type
pfmdr1-N86 from 2001 to 2007 along with low usage of AL
(Table 1) detected in this study and too soon after the policy
switch to AL is not sufficient to conclude that drug pressure
by lumefantrine might select for N86 sensitive parasites.
The studies conducted in Mozambique and Uganda re-
ported an increase in parasite population with both pfcrt-
K76 and pfmdr1-N86 wild types five years after policy
change to AL [27,51]. In addition, Henriques et, al. observed
the selection of pfcrt-K76 and pfmdr1-N86 wild types on
day 3 in their ACT efficacy trial (including AL arm) con-
ducted in Mbita, southwestern border of Kenya [28]. The
difference in the pfcrt-76 results between this study and the
report from Mozambique, Uganda and Mbita of Kenya
could be mainly due to continued use of CQ and AQ as ob-
served by the self-reported anti-malarial drug use in this
study population (Table 1). Continuous monitoring of both
pfmdr1-86 and pfcrt-76 in addition to pfmdr1-184, 1042,
1246 and pfmdr1 gene copy number will be essential in de-
tecting the emergence of lumefantrine resistance.
In this study, the drug resistance profiles were also
assessed within the context of scale up of ITNs. Theoretical
models suggest that changes in malaria transmission inten-
sity, such as by the use of vector control interventions, can
indirectly influence the spread of drug resistance through
three main clinical/epidemiological ‘mediators’. As proposed
by Hastings and Watkins, the three mediators could regulate
several effector variables: 1) the number of parasite clones
per host, which, in turn, determines the intrahost dynamics
and rate of sexual recombination; 2) the perceived threat of
infection that affects the level of community/population
drug use; or, 3) immunity against malaria, which can change
levels of therapeutic drug use and the biomass (number of
parasites) per infection [2]. Additionally, the relationship be-
tween transmission intensity and spread of drug resistance
depends on whether resistance to a drug is encoded by
single gene or by multiple genes [2]. The genetic basis of SP
is considered monogenetic as SP are encoded by dhps and
dhfr genes, respectively. Mathematical models predict
that the monogenic-based SP resistance spreads faster in
high-transmission areas compared to medium- and low-
transmission areas [2]. In contrast, CQ resistance, encoded
by two genes, pfcrt and pfmdr1 [19,49], is multigenic and
follows a concave curve such that the prevalence of resist-
ance markers is highest in low- and high-transmission areas
and lowest in areas of intermediate transmission [2,52].
This study observed the prevalence of the pfcrt-76T mu-
tation differed among areas of varying transmission inten-
sity in 2007 with the highest prevalence in the lowest
transmission area (Asembo) and lowest prevalence in
highest transmission area (Karemo) (Figure 1). In addition,
haplotype analysis of pfcrt showed that fewer samples
from Asembo were the wild type (C72V73M74N75K76)haplotype compared to Gem and Karemo (Table 2). How-
ever, there were no significant differences in the preva-
lence of pfmdr1-86Y mutation and SP dhfr/dhps
quintuple mutant genotype among the three areas (Fig-
ures 1 and 2). There are several reasons why the preva-
lence data for both CQ and SP markers from this study do
not fit the theoretical models described above. First, the
similarity in prevalence of pfmdr1, dhfr and dhps markers
among the three areas could be explained by the essen-
tially medium to high transmission and small relative dif-
ferences in transmission intensity between areas. As
noted, the difference between an EIR of 4 (Asembo and
Gem) and an EIR of 20 (Karemo) would have minimal
impact on parasite population genetic structure, resulting
in reduced ability to determine the relationship between
transmission intensity and the prevalence of molecular
markers for the three genes. It is also possible that the
gene flow due to migration of human and mosquito popu-
lations between the areas or from other parts of Kenya,
unmeasured in this study, might contribute to the lack of
difference in prevalence of the pfmdr1, dhfr and dhps gene
markers among the three areas. Second, the observed
higher prevalence of pfcrt-76T mutation and loss of more
wild type (C72V73M74N75K76) haplotype in Asembo com-
pared to the other two areas are weak although notable.
The lack of information of CQ and AQ use at the popula-
tion level for these three study areas and small sample
sizes in the reported CQ and AQ use for fever in this
study, limited the ability to explore drug pressure, influ-
enced by transmission intensity, on the observed higher
prevalence of pfcrt-76T mutation and loss of pfcrt wild
haplotype in Asmebo. However, MS data from another
study using the same set of samples showed that the over-
all proportion of multiple clone infections remained high
in 2007 but relatively lower in Asembo (88%) compared to
Karemo (97%). The relatively lower proportion of multiple
clone infections in Asembo might be associated with the
occurrence of intrahost dynamics, in which resistant para-
site clones bearing pfcrt molecular markers benefit from
removal of co-infecting drug-sensitive clones on treatment
of human host [2], resulting in high prevalence of pfcrt-
76T mutation and loss of pfcrt wild haplotype.
In this study, haplotypes based on key SNPs in pfcrt,
pfmdr1, dhfr, and dhps [44,45] were also further com-
pared between 2001 and 2007 surveys and by areas in
2007. In 2001, 23 haplotypes were found which reduced
to seven in 2007, with fewer unique haplotypes observed
in 2007. The results suggest selection of haplotype vari-
ants of multiple drug resistance genes possibly by gen-
etic recombination during the sexual reproduction stage
in mosquitoes [53] and the selection pressure could reduce
the parasite population size resulting in a more likely loss
of rare haplotypes. More importantly, an increase in the
septuple mutant (K76Y86I51R59N108G437E540) was detected
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In addition, in 2007, other two neighbouring areas, Gem
and Karemo, showed the prevalence of the septuple
haplotype mutant similar to Asembo. These results sug-
gest a strong linkage among mutations of pfcrt, pfmdr1,
dhfr, and dhps in the parasite population and a possible
effect by the strong linkage among the resistance genes
on preventing the recovery of sensitive parasites to indi-
vidual drug. The increase in the septuple mutant haplo-
type is alarming as sustained selection pressure could
promote an increase in the prevalence of septuple mu-
tant parasites to the point where both CQ and SP resist-
ance mutations eventually reach fixation in the parasite
population.
This study had a few limitations. The qualitative rank-
ing of transmission intensity based on proxies, such as
parasite prevalence, is subject to wide variation over
time. The geographic proximity of the three study areas
and evaluation of the effect of transmission intensity on
drug resistance at a single point may have also limited
the ability to detect differences in the molecular profiles
of drug resistance among the areas. The small number
of samples analysed in this study might have also re-
duced the statistical power to detect differences in the
prevalence of mutations in all the molecular markers
among the areas. In addition, the data presented here
were from samples collected in 2001 and 2007 and may
not reflect the most recent prevalence of drug resistance
markers in the study areas. Additional surveys are cur-
rently underway to genotype samples collected after
2007 from the same study areas in order to provide
more recent estimates and analyse trends in molecular
marker prevalence after a longer period of time after AL
implementation. Finally, molecular data on the preva-
lence of artemisinin resistance markers at baseline and
in more recent parasite samples from this area will be
critically important.
Conclusion
Molecular markers associated with lumefantrine resist-
ance were not detected in 2007. More recent samples will
be needed to detect any selective effects by AL. The preva-
lence of CQ and SP resistance markers increased from
2001 to 2007 in the absence of changes in transmission in-
tensity. Among these mutations, in 2007, only the preva-
lence of pfcrt-76T mutation differed among study areas of
varying transmission intensity, with the highest prevalence
in Asembo. Resistant parasites were most likely selected
by sustained drug pressure from the continued use of CQ,
SP, despite drug policy change to AL, and mechanistically
similar drugs such as AM and CTX. There was no clear
evidence that difference in transmission intensity, as a re-
sult of ITN scale-up, influenced prevalence of drug resist-
ance molecular markers.Additional file
Additional file 1: Comparison of prevalence of point mutations, by age.
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